Nurix Therapeutics Future Growth
Future criteria checks 2/6
Nurix Therapeutics's earnings are forecast to decline at 4.2% per annum while its annual revenue is expected to grow at 30% per year. EPS is expected to grow by 1.8% per annum. Return on equity is forecast to be -202.4% in 3 years.
Key information
-4.2%
Earnings growth rate
1.8%
EPS growth rate
Biotechs earnings growth | 20.6% |
Revenue growth rate | 30.0% |
Future return on equity | -202.4% |
Analyst coverage | Good |
Last updated | 25 Mar 2024 |
Recent future growth updates
Recent updates
Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet
Feb 20Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now
Jan 16Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues
Oct 14Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Oct 13Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts
Apr 18We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
Oct 06Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M
Jul 07FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.
Jun 30We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Jun 21We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
Mar 07Nurix: Advancing Targeted Protein Modulation Therapies
Nov 21Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth
Nov 21We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn
Jul 24Nurix Therapeutics appoints new operations chief
Jun 21Nurix Therapeutics adds Clay Siegall to its board of directors
Jun 01Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Apr 15Industry Analysts Just Upgraded Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Revenue Forecasts By 10%
Feb 21Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 18Rainbows and Unicorns: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Just Became A Lot More Optimistic
Jan 31Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
11/30/2026 | 89 | -247 | -259 | -201 | 7 |
11/30/2025 | 73 | -216 | -245 | -166 | 9 |
11/30/2024 | 71 | -178 | -175 | -118 | 10 |
11/30/2023 | 77 | -144 | -90 | -81 | N/A |
8/31/2023 | 69 | -149 | -154 | -146 | N/A |
5/31/2023 | 61 | -157 | -161 | -151 | N/A |
2/28/2023 | 42 | -179 | -177 | -166 | N/A |
11/30/2022 | 39 | -180 | -172 | -160 | N/A |
8/31/2022 | 39 | -171 | -163 | -153 | N/A |
5/31/2022 | 39 | -154 | -145 | -136 | N/A |
2/28/2022 | 34 | -135 | -143 | -135 | N/A |
11/30/2021 | 30 | -117 | -90 | -84 | N/A |
8/31/2021 | 29 | -99 | -80 | -74 | N/A |
5/31/2021 | 23 | -89 | -56 | -50 | N/A |
2/28/2021 | 20 | -63 | -38 | -33 | N/A |
11/30/2020 | 18 | -43 | -5 | 0 | N/A |
8/31/2020 | 13 | -37 | 3 | 8 | N/A |
5/31/2020 | 19 | -21 | 47 | 50 | N/A |
2/29/2020 | 25 | -24 | 49 | 51 | N/A |
11/30/2019 | 31 | -22 | -1 | 1 | N/A |
11/30/2018 | 37 | -9 | -33 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NRIX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NRIX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NRIX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NRIX's revenue (30% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: NRIX's revenue (30% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NRIX is forecast to be unprofitable in 3 years.